Running Interference: RNAi with Silence Therapeutics' Craig Tooman
Business Of Biotech
00:00
Gene Therapy
We're excited. We we certainly are planning for that sort of situation when we see these large markets and what's possible. Yea, so you mention tha its its genetic condition. Is there a well defined patient population for that indication? Yes, it's not that well known, but certainly well defined. So again, it's, it's probably potentially that market could be as large as the stat market over any period of time.
Transcript
Play full episode
